Infiltrating ASCs from perioprostatic WAT have also been shown to play a role in obesity driven systemic therapy resistance and prostate cancer progression via production of CXCL12 and other chemokines (90–92, 106). Here, CXCL12 is linked to obesity due to melanocortin 4 receptor deficiency.